Citadel Advisors
NYMX

Citadel Advisors’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Citadel Advisors’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,200
Closed -$15K – 9929
2019
Q2 		$15K Sell
10,200
-16,200
-61% -$28.3K ﹤0.01% 8985
2019
Q1 		$52K Buy
26,400
+14,500
+122% +$30.8K ﹤0.01% 8805
2018
Q4 		$16K Sell
11,900
-17,800
-60% -$32.6K ﹤0.01% 8827
2018
Q3 		$73K Buy
29,700
+3,000
+11% +$8.86K ﹤0.01% 8693
2018
Q2 		$90K Buy
+26,700
New +$103K ﹤0.01% 8283
2017
Q3 		– Sell
-13,600
Closed -$60K – 8205
2017
Q2 		$60K Sell
13,600
-23,700
-64% -$97.3K ﹤0.01% 7054
2017
Q1 		$135K Sell
37,300
-11,700
-24% -$38.5K ﹤0.01% 6739
2016
Q4 		$131K Buy
49,000
+36,500
+292% +$113K ﹤0.01% 6568
2016
Q3 		$41K Buy
+12,500
New +$40.9K ﹤0.01% 6893
2015
Q3 		– Sell
-800
Closed -$1K – 9337
2015
Q2 		$1K Sell
800
-100
-11% -$140 ﹤0.01% 8654
2015
Q1 		$1K Buy
+900
New +$425 ﹤0.01% 8465
2014
Q4 		– Sell
-4,400
Closed -$19K – 8808
2014
Q3 		$19K Sell
4,400
-4,300
-49% -$21.1K ﹤0.01% 7495
2014
Q2 		$43K Buy
+8,700
New +$44.8K ﹤0.01% 6861

Other funds holding NYMX

DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
CAM
Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return
ODIJL
One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Citadel Advisors's NYMX Position: Q3 2023 in Review

Citadel Advisors sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 25,040 shares — an estimated $4.76K sold.

Citadel Advisors first reported a position in NYMX in Q1 2014 and held it in 20 quarters. The position peaked at $216K in Q1 2014. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

  • Citadel Advisors reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 25,040 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $4.76K.
  • Citadel Advisors first reported a position in Nymox Pharmaceutical Corp in Q1 2014 and held it in 20 quarters.
  • Citadel Advisors's Nymox Pharmaceutical Corp position peaked at $216K in Q1 2014.
  • 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.